GMED vs GKOS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 23, 2026

GMED

37.4
AI Score
VS
GKOS Wins

GKOS

39.5
AI Score

Investment Advisor Scores

GMED

37score
Recommendation
AVOID NEW MONEY

GKOS

40score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric GMED GKOS Winner
Forward P/E 13.8696 1666.6667 GMED
PEG Ratio 1.7253 1.64 GKOS
Revenue Growth 5.9% 49.5% GKOS
Earnings Growth -26.2% 1896.3% GKOS
Tradestie Score 37.4/100 39.5/100 GKOS
Profit Margin 17.0% -30.7% GMED
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY AVOID NEW MONEY Tie

Relative Price Performance (Last 90 Days)

GMED 1M: +9.7% · 3M: +4.1% GKOS 1M: +15.6% · 3M: +17.9%

Current Technical Phase

GMED

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 63

RSI (14): 63.3 · Price: $81.47

GKOS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 63

RSI (14): 62.9 · Price: $179.06

Fundamentals Snapshot

Metric GMED GKOS
Market Cap — —
Forward P/E 15.2 338.0
Trailing P/E 20.2 —
Revenue (TTM) — —
Revenue Growth 0.1% 0.5%
Gross Margin 0.7% 0.8%
Operating Margin 0.2% -0.1%
EPS 3.90 -3.26
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, GKOS is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.